Atara Biotherapeutics (ATRA) Sidoti Micro-Cap Virtual Conference summary

Company overview and platform differentiation

• Leading allogeneic T-cell therapy platform, first to receive regulatory approval for an allogeneic T-cell therapy, currently commercialized in Europe.

• Platform leverages Epstein-Barr virus (EBV) T-cells from healthy donors, enabling off-the-shelf therapies with rapid delivery to patients.

• Allogeneic approach avoids gene editing, reducing risks of chromosomal abnormalities and manufacturing inefficiencies.

• Partial HLA matching and EBV specificity minimize immunogenicity and host rejection, with over 600 patients treated and no graft-versus-host disease observed.

• Outpatient administration possible, with no need for lymphodepletion or apheresis, differentiating from autologous CAR-T therapies.

Pipeline and clinical milestones

• ATA3219 (CD19 CAR-T) in phase I for non-Hodgkin's lymphoma, with initial data expected Q1 2025.

• Autoimmune program includes lupus nephritis and severe SLE cohorts, with phase I initiation in Q4 2024 and data readout mid-2025.

• ATA3431 (CD19/CD20 dual CAR-T) IND planned for second half of 2025, targeting resistance mechanisms in oncology.

• Tabelecleucel (tab-cel) approved in Europe, BLA accepted in the US with PDUFA date January 15, 2025.

• Over 600 patients treated across programs, supporting safety and efficacy claims.

Market opportunity and competitive landscape

• Allogeneic platform addresses scalability and access limitations of autologous CAR-T, especially for large autoimmune indications.

• Current autologous CAR-T therapies face capacity, durability, and safety challenges, limiting patient access to 20%-40% of eligible cases.

• Allogeneic approach enables broader reach, including community centers, and aims for improved durability and safety.

• Preclinical data show superior persistence and efficacy compared to autologous benchmarks.

• Industry-wide momentum in CAR-T for autoimmune diseases, with high unmet need and limited approved therapies.